Table 3.
Anticonvulsant activity and neurotoxicity of compounds in the 6 Hz model following intraperitoneal (ip.) administration in mice.
| Compound | Test a | 0.25 h | 0.5 h | 1.0 h | 2.0 h | 4.0 h |
|---|---|---|---|---|---|---|
| (4R,8aR)-3a | 6 Hz b | 4/4 | 4/4 | 1/4 | 1/4 | 0/4 |
| TOX c | - | - | - | - | - | |
| (4S,9aS)-3c | 6 Hz | 1/4 | 2/4 | 0/4 | 0/4 | 0/4 |
| TOX | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | |
| (4R,9aR)-3c | 6 Hz | 3/4 | 1/4 | 1/4 | 1/4 | 0/4 |
| TOX | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | |
| (4S,8aS)-3d | 6 Hz | 1/4 | 1/4 | 0/4 | 0/4 | 0/4 |
| TOX | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | |
| (4R,8aR)-3d | 6 Hz | 3/4 | 2/4 | 0/4 | 0/4 | 0/4 |
| TOX | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | |
| (8aS)-3e | 6 Hz | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| TOX | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | |
| (8aR)-3e | 6 Hz | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| TOX | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | |
| (8aS)-3f | 6 Hz | - | 0/4 | - | 1/4 | - |
| TOX | - | 1/4 | - | 0/4 | - | |
| (8aR)-3f | 6 Hz d | 0/4 | 0/4 | 1/3 | 0/4 | 1/4 |
| TOX d | 2/4 e | 1/4 e | 1/4 f | 0/4 | 0/4 | |
| (8aS)-3g | 6 Hz | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| TOX | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | |
| (8aR)-3g | 6 Hz d | 1/2 | 2/2 | 2/2 | 3/3 | 0/4 |
| TOX d | 4/4 e,g,h,i | 2/4 g | 2/4 g | 1/4 f | 0/4 | |
| (4S,8aS)-3h | 6 Hz j | 1/4 | 3/4 | 0/4 | 0/4 | 0/4 |
| TOX j | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | |
| (4S,8aS)-6 | 6 Hz | 3/4 | 2/4 | 2/4 | 0/4 | 0/4 |
| TOX | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |
a At dose 100 mg/kg; b 6 Hz test, 32 mA (number of animals protected/number of animals tested); c Neurotoxicity test (number of animals exhibiting neurological toxicity/number of animals tested); d At dose 50 mg/kg; e Clonic seizures; f One animal died; g Two animals died; h Unable to grasp rotorod; i Tremors; j At dose 75 mg/kg.